SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3557 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2707Lucentis 1Q ex-US sale were $533M. Not bad....Miljenko Zuanic-4/25/2019
2706Ya I can't think of anything unique about their Ab that would avoid these siFelix B-4/24/2019
2705PfE/LLY tanezumab, after dose was cut to *safety* level, did not perform as wellMiljenko Zuanic-4/19/2019
2704Happy Easter!Miljenko Zuanic-4/19/2019
2703Last fare-sale correction was at Christmas. This one is at Easter. Next one at HMiljenko Zuanic-4/18/2019
2702<What is CHF? > Swiss currency, franc. No, Lucentis Q-sale are steady (didMiljenko Zuanic-4/18/2019
2701Valid point, didn't consider that. I thought eylea may have established braFelix B-4/17/2019
2700What is CHF? So you are assuming any loss in Lucentis is going to Eylea? CouldFelix B-4/17/2019
2699Roche 1Q results, Lucentis (US) at 457 CHF growth ~6% over 4Q (432). Expecting Miljenko Zuanic-4/17/2019
2698I haven't done any modeling of this yet.DewDiligence_on_SI-4/16/2019
2697How you see now Eylea enterprise (market) value?Miljenko Zuanic-4/16/2019
2696In Street eyes, is ALNY collaboration that bad? On their own where are they headMiljenko Zuanic-4/16/2019
2695RTH258 will certainly take some share, and it may cause some price erosion for EDewDiligence_on_SI-4/16/2019
2694I think REGN has a pretty good trench with Eylea and RTH258 doesn't offer anFelix B-4/15/2019
2693RTH258: novartis.comDewDiligence_on_SI-4/15/2019
2692RGNX is bussy! seekingalpha.comMiljenko Zuanic-4/15/2019
2691Lp(a) additional risk factor for CVD: pcsk9forum.orgMiljenko Zuanic-4/15/2019
2690RE:ADVM First cohort (6 subjects) enrolled, clinical hold due to CMC finance.yahMiljenko Zuanic-4/15/2019
2689We all know well that liver is *cleaning* organ, prone to suck everything bad inMiljenko Zuanic-4/13/2019
2688Indeed when liver is target, active dose reduction and Q-dosing interval is applMiljenko Zuanic-4/13/2019
2687Remarkable results for givosiran.nigel bates-4/13/2019
2686Always appreciate your posts Miljenko! Just curious, can you explain more on noFelix B-4/12/2019
2685They may have some early stage discovery programs for wet/dry-AMD. One of the poMiljenko Zuanic-4/9/2019
2684I don't think that info is probative as to whether the new collaboration incDewDiligence_on_SI-4/9/2019
2683From the ALNY pre-clinical presentation on CNS/Ocular new siRNA constructs (httpMiljenko Zuanic-4/9/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News